Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

BACKGROUND: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rov...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet Oncol
Päätekijät: Rudin, Charles M, Pietanza, M Catherine, Bauer, Todd M, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S, Byers, Lauren A, Johnson, Melissa L, Burris, Howard A, Robert, Francisco, Han, Tae H, Bheddah, Sheila, Theiss, Noah, Watson, Sky, Mathur, Deepan, Vennapusa, Bharathi, Zayed, Hany, Lally, Satwant, Strickland, Donald K, Govindan, Ramaswamy, Dylla, Scott J, Peng, Stanford L, Spigel, David R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5481162/
https://ncbi.nlm.nih.gov/pubmed/27932068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30565-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia